Syndax Pharmaceuticals Reports 82% Year-over-Year Revenue Growth in Q3
Syndax Pharmaceuticals (SNDX) reported strong third-quarter financial results, highlighted by a total revenue of $83 million, representing an 82% increase compared to the previous year. CEO Michael Metzger noted that the company is seeing significant commercial growth and pipeline momentum as it works toward achieving profitability. A key driver for future growth is the drug Revuforj, which management anticipates could exceed $2 billion in peak annual net revenue in the United States. This projection is supported by expected expansion into post-transplant maintenance markets.
Tickers: $SNDX
Topics: commercial performance profitability quarterly earnings revenue growth
Read the full article at Seeking Alpha
Part of the story Topaz Energy Reports Q3 Revenue Growth of 36.4% Year-over-Year (3 articles)